Contact this trialFirst, we need to learn more about you.
Immunomodulator
Ruxolitinib for Chronic Graft-versus-Host Disease
Recruiting1 awardPhase 1
Cincinnati, Ohio
"This trial is studying the effectiveness of a new drug called ruxolitinib in treating chronic graft versus host disease (cGVHD) which is a common complication after a stem cell transplant. R
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service